Modulating CPS1 Expression to Enhance Ureagenesis in Urea Cycle Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for urea cycle disorders are limited, with a high unmet need for effective therapeutics, as existing methods often require lifelong management, dietary restrictions, and have limitations such as costly liver transplants and side effects from immunosuppressants.
Innovation Solution
The use of compounds that increase CPS1 expression by inhibiting targets like JAK1, JAK2, HSP90, or IRF9 to enhance OTC gene expression and ureagenesis, thereby increasing serum urea levels, which can be achieved through the administration of specific small molecules or siRNA compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver transplant is performed to treat severe urea cycle disorders, then ammonia clearance function is restored, but treatment cost increases and patients face side effects from immunosuppressants
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to modulate the expression of urea cycle enzymes (CPS1, OTC, ASS1, ASL, ARG1) endogenously. These compounds act as mediators between the patient's own genetic machinery and the desired therapeutic outcome, avoiding the need for external organ transplantation and immunosuppression
Solution Approach 2:
The invention enables the patient's liver to self-correct the urea cycle defect by upregulating enzyme expression through pharmacological modulation. The body's own cellular machinery is activated to produce sufficient functional enzyme activity, making the system self-sufficient without requiring transplant organs or lifelong immunosuppressant therapy
2Quantity of substance
If dietary protein restriction is implemented to manage urea cycle disorders, then ammonia production is reduced, but patient nutrition and quality of life deteriorate
Solution Approach 1:
The patent changes the biochemical parameter of enzyme expression levels rather than restricting substrate availability. By upregulating urea cycle enzyme expression through small molecule compounds, the system increases ammonia clearance capacity without limiting dietary protein intake, thereby maintaining normal nutrition while controlling ammonia levels
3Quantity of substance
If nitrogen binding agents are used to excrete excess nitrogen, then urea cycle function is bypassed, but treatment complexity and cost increase
Solution Approach 1:
Instead of bypassing the defective urea cycle with alternative nitrogen excretion pathways (which adds treatment complexity), the invention converts the harmful accumulation of ammonia into beneficial urea production by enhancing the existing urea cycle pathway through enzyme upregulation. This transforms the defective system into a functional one, eliminating the need for complex bypass therapies
Data Source
AI summary
Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.